Asian Growth Companies With High Insider Ownership In March 2025

As global markets navigate a landscape marked by economic uncertainty and shifting monetary policies, the Asian market has shown resilience with mixed performances across major indices. Amid these conditions, growth companies with high insider ownership present intriguing opportunities as they often reflect strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership In Asia

Click here to see the full list of 648 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Shenzhen Bluetrum Technology (SHSE:688332)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Shenzhen Bluetrum Technology Co., Ltd. focuses on the R&D, design, and sale of wireless audio SOC chips in China, with a market cap of CN¥14.68 billion.

Operations: The company's revenue is primarily derived from the research, development, design, and sale of wireless audio SOC chips in China.

Insider Ownership: 26.3%

Revenue Growth Forecast: 22.1% p.a.

Shenzhen Bluetrum Technology shows promising revenue growth, forecasted at 22.1% per year, outpacing the broader Chinese market. Despite a recent earnings increase to CNY 300.47 million, its profit growth is expected to lag behind the market at 20.9%. The company's price-to-earnings ratio of 52.6x suggests it is undervalued compared to industry peers, though its share price remains volatile and dividends are unstable. No significant insider trading activity was reported recently.

• Navigate through the intricacies of Shenzhen Bluetrum Technology with our comprehensive analyst estimates report here.
• Our comprehensive valuation report raises the possibility that Shenzhen Bluetrum Technology is priced higher than what may be justified by its financials.

Circuit Fabology Microelectronics EquipmentLtd (SHSE:688630)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Circuit Fabology Microelectronics Equipment Co., Ltd. (ticker: SHSE:688630) specializes in the production of microelectronics equipment and has a market capitalization of approximately CN¥8.64 billion.

Operations: Circuit Fabology Microelectronics Equipment Co., Ltd. (ticker: SHSE:688630) specializes in the production of microelectronics equipment and has a market capitalization of approximately CN¥8.64 billion. Revenue Segments (in millions of CN¥): [No specific revenue segments provided in the text].

Insider Ownership: 29.7%

Revenue Growth Forecast: 29.1% p.a.

Circuit Fabology Microelectronics Equipment Ltd. is positioned for robust growth, with revenue expected to increase by 29.1% annually, surpassing the Chinese market's average. Earnings are forecasted to grow significantly at 37.3% per year, outpacing the market's 24.9%. Despite a low return on equity forecast of 15.7%, its price-to-earnings ratio of 55.9x indicates relative value in the semiconductor sector. Recent earnings showed sales growth but a decline in net income to CNY 164.9 million from CNY 179.31 million last year, and dividends remain poorly covered by free cash flows.

• Delve into the full analysis future growth report here for a deeper understanding of Circuit Fabology Microelectronics EquipmentLtd.
• The valuation report we've compiled suggests that Circuit Fabology Microelectronics EquipmentLtd's current price could be inflated.

Porton Pharma Solutions (SZSE:300363)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Porton Pharma Solutions Ltd. is a CDMO that offers development and manufacturing services for small molecules, tides, biologics, and conjugates from pre-clinical to commercial stages, with a market cap of CN¥9.25 billion.

Operations: Porton Pharma Solutions Ltd. generates revenue through its contract development and manufacturing services, focusing on small molecules, tides, biologics, and conjugates across various stages from pre-clinical to commercial.

Insider Ownership: 26.7%

Revenue Growth Forecast: 20.6% p.a.

Porton Pharma Solutions is poised for significant growth, with revenue expected to increase by 20.6% annually, outpacing the Chinese market's 13% growth rate. Earnings are projected to grow substantially at a rate of 123.94% per year, although the return on equity is forecasted to remain low at 5.3%. The company's dividend yield of 2.63% is not well covered by earnings or free cash flows, and there has been no substantial insider trading activity recently.

• Click here to discover the nuances of Porton Pharma Solutions with our detailed analytical future growth report.
• In light of our recent valuation report, it seems possible that Porton Pharma Solutions is trading beyond its estimated value.

Taking Advantage

• Explore the 648 names from our Fast Growing Asian Companies With High Insider Ownership screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com